Treatment-resistant depression is a common psychiatric disorder that can lead to significant disability and decreased quality of life for patients. In recent years, there has been growing interest in the combination of intravenous ketamine and electroconvulsive therapy (ECT) for the treatment of treatmentresistant depression. Ketamine is an anesthetic that is an N-methyl-D-aspartate (NMDA) receptor antagonist that also has antidepressant properties and has been used to treat treatment-resistant depression. ECT is a treatment for depression that involves applying electric current to the brain to induce therapeutic seizures. Recent studies have shown that the combination of intravenous ketamine and ECT can be an effective treatment for treatment-resistant depression. Although more research is still needed to fully understand the efficacy and safety of the combination of intravenous ketamine and ECT for the treatment of treatment-resistant depression, combination therapy may be a promising option for patients who do not respond to other treatments.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.